RSK4 knockdown promotes proliferation, migration and metastasis of human breast adenocarcinoma cells

Zhu,Jia; Li,Qiu-Yun; Liu,Jian-Lun; Wei,Wei; Yang,Hua-Wei; Tang,Wei

doi:10.3892/or.2015.4291

RSK4 knockdown promotes proliferation, migration and metastasis of human breast adenocarcinoma cells

Authors:
- Jia Zhu
- Qiu-Yun Li
- Jian-Lun Liu
- Wei Wei
- Hua-Wei Yang
- Wei Tang
View Affiliations

Affiliations: Department of Breast Surgery, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China
Published online on: September 18, 2015 https://doi.org/10.3892/or.2015.4291
Pages: 3156-3162

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

RSK4 has been shown to inhibit the growth of certain cancer cells. The aim of this study was to construct a lentiviral vector of RSK4-shRNA (Lenti-RSK4-shRNA) to specifically block the expression of RSK4 in the human breast adenocarcinoma cell line MCF-7, and investigate the effect of the RSK4 gene on cell proliferation and invasion in vitro and in vivo. Lenti-RSK4-shRNA was stably transfected into MCF-7 cells. RSK4 mRNA and protein expression were measured by fluorescence quantitative RT-PCR and western blot analysis. Cell proliferation was evaluated by MTT assays and flow cytometric analysis. Invasion was evaluated by Transwell assays and xenograft nude mouse models. The expression of RSK4 mRNA, Ki-67 mRNA, cyclin D1 mRNA, CXCR4 mRNA and E-cadherin mRNA of tumor xenografts were detected by fluorescence quantitative RT-PCR. Significant decreases in RSK4 mRNA and protein expression was detected in MCF-7 cells carrying lentiviral RSK4-shRNA vector. The cell proliferation was significantly promoted in the RSK4-shRNA group as compared to that in the negative and blank control group. In addition, the number of cells in the S phase in the RSK4‑shRNA group was significantly greater than the blank and negative control groups (P<0.05). Furthermore, the number of invading cells was increased in the RSK4-shRNA (P<0.05). In vivo, we also found that the knockdown of RSK4 promoted tumorigenicity and migration in the xenograft nude mouse model. In addition, we showed that the RSK4 mRNA and E-cadherin mRNA expression were significantly lower in the RSK4-shRNA group compared to that in negative and blank control group (both P<0.05), while the Ki-67 mRNA, cyclin D1 mRNA and CXCR4 mRNA were higher in the shRNA group compared to that in negative and blank control group (both P<0.05). In conclusion, downregulation of RSK4 expression is indicated to be associated with tumor cell proliferation and invasion, and silencing of the RSK4 may be involved in the development and progression of breast cancer through the changes of Ki-67, cyclin D1, CXCR4 and E-cadherin, and suggesting that RSK4 may act as a potential cancer suppressor gene and therapeutic target for the treatment of breast cancer.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Dent R, Valentini A, Hanna W, Rawlinson E, Rakovitch E, Sun P and Narod SA: Factors associated with breast cancer mortality after local recurrence. Curr Oncol. 21:e418–e425. 2014. View Article : Google Scholar : PubMed/NCBI
3	Fischgräbe J and Wülfing P: Targeted therapies in breast cancer: Established drugs and recent developments. Curr Clin Pharmacol. 3:85–98. 2008. View Article : Google Scholar : PubMed/NCBI
4	Frödin M and Gammeltoft S: Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction. Mol Cell Endocrinol. 151:65–77. 1999. View Article : Google Scholar : PubMed/NCBI
5	Anjum R and Blenis J: The RSK family of kinases: Emerging roles in cellular signalling. Nat Rev Mol Cell Biol. 9:747–758. 2008. View Article : Google Scholar : PubMed/NCBI
6	Nebreda AR and Gavin AC: Perspectives: Signal transduction. Cell survival demands some Rsk. Science. 286:1309–1310. 1999. View Article : Google Scholar : PubMed/NCBI
7	Yntema HG, van den Helm B, Kissing J, van Duijnhoven G, Poppelaars F, Chelly J, Moraine C, Fryns JP, Hamel BC, Heilbronner H, et al: A novel ribosomal S6-kinase (RSK4; RPS6KA6) is commonly deleted in patients with complex X-linked mental retardation. Genomics. 62:332–343. 1999. View Article : Google Scholar
8	Roux PP and Blenis J: ERK and p38 MAPK-activated protein kinases: A family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev. 68:320–344. 2004. View Article : Google Scholar : PubMed/NCBI
9	Roux PP, Ballif BA, Anjum R, Gygi SP and Blenis J: Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci USA. 101:13489–13494. 2004. View Article : Google Scholar : PubMed/NCBI
10	Yang X, Matsuda K, Bialek P, Jacquot S, Masuoka HC, Schinke T, Li L, Brancorsini S, Sassone-Corsi P, Townes TM, et al: ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin-Lowry syndrome. Cell. 117:387–398. 2004. View Article : Google Scholar : PubMed/NCBI
11	Woo MS, Ohta Y, Rabinovitz I, Stossel TP and Blenis J: Ribosomal S6 kinase (RSK) regulates phosphorylation of filamin A on an important regulatory site. Mol Cell Biol. 24:3025–3035. 2004. View Article : Google Scholar : PubMed/NCBI
12	Dümmler BA, Hauge C, Silber J, Yntema HG, Kruse LS, Kofoed B, Hemmings BA, Alessi DR and Frödin M: Functional characterization of human RSK4, a new 90-kDa ribosomal S6 kinase, reveals constitutive activation in most cell types. J Biol Chem. 280:13304–13314. 2005. View Article : Google Scholar : PubMed/NCBI
13	Thakur A, Sun Y, Bollig A, Wu J, Biliran H, Banerjee S, Sarkar FH and Liao DJ: Anti-invasive and antimetastatic activities of ribosomal protein S6 kinase 4 in breast cancer cells. Clin Cancer Res. 14:4427–4436. 2008. View Article : Google Scholar : PubMed/NCBI
14	López-Vicente L, Armengol G, Pons B, Coch L, Argelaguet E, Lleonart M, Hernández-Losa J, de Torres I and Ramon y Cajal S: Regulation of replicative and stress-induced senescence by RSK4, which is down-regulated in human tumors. Clin Cancer Res. 15:4546–4553. 2009. View Article : Google Scholar : PubMed/NCBI
15	Elbashir SM, Lendeckel W and Tuschl T: RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 15:188–200. 2001. View Article : Google Scholar : PubMed/NCBI
16	Sen GL and Blau HM: A brief history of RNAi: The silence of the genes. FASEB J. 20:1293–1299. 2006. View Article : Google Scholar : PubMed/NCBI
17	Myers AP, Corson LB, Rossant J and Baker JC: Characterization of mouse Rsk4 as an inhibitor of fibroblast growth factor-RAS-extracellular signal-regulated kinase signaling. Mol Cell Biol. 24:4255–4266. 2004. View Article : Google Scholar : PubMed/NCBI
18	Berns K, Hijmans EM, Mullenders J, Brummelkamp TR, Velds A, Heimerikx M, Kerkhoven RM, Madiredjo M, Nijkamp W, Weigelt B, et al: A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature. 428:431–437. 2004. View Article : Google Scholar : PubMed/NCBI
19	Thakur A, Rahman KW, Wu J, Bollig A, Biliran H, Lin X, Nassar H, Grignon DJ, Sarkar FH and Liao JD: Aberrant expression of X-linked genes RbAp46, Rsk4, and Cldn2 in breast cancer. Mol Cancer Res. 5:171–181. 2007. View Article : Google Scholar : PubMed/NCBI
20	Sharp PA: RNA interference - 2001. Genes Dev. 15:485–490. 2001. View Article : Google Scholar : PubMed/NCBI
21	Hannon GJ and Rossi JJ: Unlocking the potential of the human genome with RNA interference. Nature. 431:371–378. 2004. View Article : Google Scholar : PubMed/NCBI
22	Stewart SA, Dykxhoorn DM, Palliser D, Mizuno H, Yu EY, An DS, Sabatini DM, Chen IS, Hahn WC, Sharp PA, et al: Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA. 9:493–501. 2003. View Article : Google Scholar : PubMed/NCBI
23	McIntosh GG, Anderson JJ, Milton I, Steward M, Parr AH, Thomas MD, Henry JA, Angus B, Lennard TW and Horne CH: Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene. 11:885–891. 1995.PubMed/NCBI
24	Vos CB, Ter Haar NT, Peterse JL, Cornelisse CJ and van de Vijver MJ: Cyclin D1 gene amplification and overexpression are present in ductal carcinoma in situ of the breast. J Pathol. 187:279–284. 1999. View Article : Google Scholar : PubMed/NCBI
25	Oyama T, Kashiwabara K, Yoshimoto K, Arnold A and Koerner F: Frequent overexpression of the cyclin D1 oncogene in invasive lobular carcinoma of the breast. Cancer Res. 58:2876–2880. 1998.PubMed/NCBI
26	Bilalović N, Vranić S, Basić H, Tatarević A and Selak I: Immunohistochemical evaluation of cyclin D1 in breast cancer. Croat Med J. 46:382–388. 2005.
27	Niewiadomska H, Jeziorski A and Olborski B: The expression of the proliferating antigen Ki67, PCNA and products of suppressor gene p53 in primary invasive ductal breast carcinoma. J Exp Clin Cancer Res. 17:503–510. 1998.
28	Zhou CJ, Zhang QH, Zhang TG, Sun SZ, Li H, Wang Y and Liu ZY: Expression of ER, Ki-67 and cylinD1 in the pre-cancerous breast of Chinese patients. Pathol Oncol Res. 15:153–158. 2009. View Article : Google Scholar
29	Shargh SA, Sakizli M, Khalaj V, Movafagh A, Yazdi H, Hagigatjou E, Sayad A, Mansouri N, Mortazavi-Tabatabaei SA and Khorram Khorshid HR: Downregulation of E-cadherin expression in breast cancer by promoter hypermethylation and its relation with progression and prognosis of tumor. Med Oncol. 31:2502014. View Article : Google Scholar : PubMed/NCBI
30	Siitonen SM, Kononen JT, Helin HJ, Rantala IS, Holli KA and Isola JJ: Reduced E-cadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer. Am J Clin Pathol. 105:394–402. 1996.PubMed/NCBI
31	Furusato B, Mohamed A, Uhlén M and Rhim JS: CXCR4 and cancer. Pathol Int. 60:497–505. 2010. View Article : Google Scholar : PubMed/NCBI